Table 1 Characteristics of patients with hepatocellular cancer
Median | Range | |
|---|---|---|
Age | 66.7 | 45.1 - 83.7 |
Survival | 14.5 | 1.1 - 25.1 |
Number | Percentage (%) | |
Total | 50 | 100 |
Gender | ||
Female | 8 | 16.0 |
Male | 42 | 84.0 |
Cirrhosis | 37 | 74.0 |
Child-Pugh stage | ||
A | 20 | 40.0 |
B | 14 | 28.0 |
C | 3 | 6.0 |
Risk factors | ||
Hepatitis B positive | 2 | 4.0 |
Hepatitis C positive | 8 | 16.0 |
HBV + HCV | 3 | 6.0 |
Alcohol-induced cirrhosis | 21 | 42.0 |
Alcohol + HCV | 1 | 2.0 |
Number of tumors | ||
single lesion | 13 | 26.0 |
double lesions | 8 | 16.0 |
multiple lesions | 29 | 58.0 |
Tumor size | ||
≤ 1 cm | 2 | 4.0 |
≤ 3 cm | 14 | 28.0 |
≤ 5 cm | 17 | 34.0 |
≤ 10 cm | 13 | 26.0 |
> 10 cm | 4 | 8.0 |
T-stage | ||
T1 | 10 | 20.0 |
T2 | 4 | 8.0 |
T3 | 36 | 72.0 |
Treatments before TACE | ||
Resection | 5 | 10.0 |
PEI | 2 | 4.0 |
Indication of TACE | ||
Palliative | 33 | 66.0 |
Bridging | 5 | 10.0 |
bridging (plus RFA) | 1 | 2.0 |
palliative (plus RFA) | 5 | 10.0 |
palliative after prior resection | 5 | 10.0 |
Treatments after TACE | ||
TACE | 21 | 42.0 |
Sorafenib | 7 | 14.0 |
TACE and Sorafenib | 4 | 8.0 |
LTX | 6 | 12.0 |
Time of study entry | ||
1st application | 21 | 42.0 |
2nd-further application | 29 | 58.0 |
Total therapies | 77 | 100 |
Therapy | ||
TACE | 71 | 92.2 |
TACE + RFA | 6 | 7.8 |
Number of TACE cycle | ||
1 | 21 | 29.6 |
2 | 20 | 28.2 |
3 | 16 | 22.5 |
4 | 7 | 9.9 |
≥5 | 7 | 9.9 |
Time of CT- and MRI-Scan after TACE | ||
< 60 days | 20 | 28.2 |
60 - 90 days | 36 | 50.7 |
> 90 days | 15 | 21.1 |
Therapy response (TACE alone) | ||
REM | 2 | 2.8 |
SD | 30 | 42.3 |
PD | 39 | 54.9 |